Noa G. Holtzman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Noa G. Holtzman has a total of 162 co-authors. Here are the top co-authors by number of shared publications:
- Steven Z. Pavletic
Immune Deficiency Cellular Therapy Program, National Cancer Institute, Bethesda, Maryland
6 shared publications - Filip Pirsl
Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD, USA
4 shared publications Steven Z. Pavletic
National Cancer Institute, Bethesda, Maryland, United States
4 shared publications- Alen Ostojic
Immune Deficiency Cellular Therapy Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD
3 shared publications - Eduard Schulz
Division of Hematology, Department of Internal Medicine, Medical University of Graz, Graz, Austria
3 shared publications Frances T. Hakim
National Cancer Institute, Bethesda, Maryland, United States
3 shared publications
Latest Publications
- Open Access
- 28 July 2026
- Published by Wiley in American Journal of Hematology
- Vol. 101 (10) , 2691-2695
Dasatinib Exposure and Risk of CMV Reactivation in Philadelphia Chromosome‐Positive Acute Lymphoblastic Leukemia
- 28 July 2026
- Published by Wiley in American Journal of Hematology
- Vol. 101 (10) , 2691-2695
Open AccessDasatinib Exposure and Risk of CMV Reactivation in Philadelphia Chromosome‐Positive Acute Lymphoblastic Leukemia
- Open Access
- 27 May 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (17) , 5751-5761
Baricitinib for refractory chronic graft-versus-host-disease: Results of a phase 1/2 study.
Refractory chronic graft-versus-host disease (cGVHD) after allogeneic hematopoietic cell transplantation remains a leading cause of late morbidity and mortality for transplant survivors. Therapeutic targeting of the JAK-STAT pathway has proved to be an effective approach for cGVHD, however toxicities and short response durability have been limiting use of available agents. The safety and efficacy of the JAK 1/2 inhibitor baricitinib was investigated in patients with severe cGVHD refractory to at least two lines of therapy. This single center phase 1/2 study (NCT0275973) enrolled twenty-four adult patients who received two dose levels of baricitinib of 2- and 4-mg daily in an intra-patient dose escalation study design. No dose limiting toxicities were observed at either dose level. ORR at 6-months was 76.2% (95%CI, 52.8-91.8), with responses observed across all involved organs including sclerotic skin and pulmonary. Median FFS was 19 months (95%CI, 11-26) with no deaths or malignancy relapse on treatment. Clinically meaningful improvements in patient-reported- and functional outcomes were seen in this highly morbid cohort. Immune correlative studies showed that baricitinib induced significant reductions in cytokine-induced signaling (pSTAT) in both CD4+ and CD8+ T cells, and in proinflammatory cytokine secretion. Baricitinib was well tolerated and exhibited a high rate of durable responses in a severely affected cohort of cGVHD patients, warranting further evaluation in earlier line and larger scale studies.
- 27 May 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (17) , 5751-5761
Open AccessBaricitinib for refractory chronic graft-versus-host-disease: Results of a phase 1/2 study.
Refractory chronic graft-versus-host disease (cGVHD) after allogeneic hematopoietic cell transplantation remains a leading cause of late morbidity and mortality for transplant survivors. Therapeutic targeting of the JAK-STAT pathway has proved to be an effective approach for cGVHD, however toxicities and short response durability have been limiting use of available agents. The safety and efficacy of the JAK 1/2 inhibitor baricitinib was investigated in patients with severe cGVHD refractory to at least two lines of therapy. This single center phase 1/2 study (NCT0275973) enrolled twenty-four adult patients who received two dose levels of baricitinib of 2- and 4-mg daily in an intra-patient dose escalation study design. No dose limiting toxicities were observed at either dose level. ORR at 6-months was 76.2% (95%CI, 52.8-91.8), with responses observed across all involved organs including sclerotic skin and pulmonary. Median FFS was 19 months (95%CI, 11-26) with no deaths or malignancy relapse on treatment. Clinically meaningful improvements in patient-reported- and functional outcomes were seen in this highly morbid cohort. Immune correlative studies showed that baricitinib induced significant reductions in cytokine-induced signaling (pSTAT) in both CD4+ and CD8+ T cells, and in proinflammatory cytokine secretion. Baricitinib was well tolerated and exhibited a high rate of durable responses in a severely affected cohort of cGVHD patients, warranting further evaluation in earlier line and larger scale studies.
- Open Access
- 24 July 2025
- Published by Wiley in British Journal of Haematology
- Vol. 207 (4) , 1178-1191
CD123‐targeting immunotherapeutic approaches in acute myeloid leukaemia
Summary: Treatment of relapsed or refractory acute myeloid leukaemia (AML) has remained a significant challenge, with limited available targeted immunotherapies. CD123, or the interleukin‐3 (IL‐3) receptor, has long been known as a potential target expressed on AML blasts, and a range of different approaches to targeting CD123 have been trialled with variable anti‐tumour responses and toxicities observed. Here, we review the clinical outcomes of these therapies, including monoclonal antibodies and antibody‐drug conjugates, as well as bispecific T‐cell engager molecules and chimeric antigen receptor (CAR) T cells. We discuss the potential reasons for therapy‐associated toxicity and limited efficacy, including differential antigen expression, the AML microenvironment and patient‐derived T‐cell fitness. To address these challenges, we highlight novel approaches to CD123 targeting currently in preclinical development. Promising new strategies include combination therapies that target CD123 and other known AML‐associated antigens such as CD33 or CLL‐1, NK‐cell‐based cell therapies, and bispecific‐secreting T cells.
- 24 July 2025
- Published by Wiley in British Journal of Haematology
- Vol. 207 (4) , 1178-1191
Open AccessCD123‐targeting immunotherapeutic approaches in acute myeloid leukaemia
Summary: Treatment of relapsed or refractory acute myeloid leukaemia (AML) has remained a significant challenge, with limited available targeted immunotherapies. CD123, or the interleukin‐3 (IL‐3) receptor, has long been known as a potential target expressed on AML blasts, and a range of different approaches to targeting CD123 have been trialled with variable anti‐tumour responses and toxicities observed. Here, we review the clinical outcomes of these therapies, including monoclonal antibodies and antibody‐drug conjugates, as well as bispecific T‐cell engager molecules and chimeric antigen receptor (CAR) T cells. We discuss the potential reasons for therapy‐associated toxicity and limited efficacy, including differential antigen expression, the AML microenvironment and patient‐derived T‐cell fitness. To address these challenges, we highlight novel approaches to CD123 targeting currently in preclinical development. Promising new strategies include combination therapies that target CD123 and other known AML‐associated antigens such as CD33 or CLL‐1, NK‐cell‐based cell therapies, and bispecific‐secreting T cells.
- Open Access
- 10 July 2025
- Published by American Society of Hematology in Blood Advances
- Vol. 9 (14) , 3479-3494
Belumosudil reduces oral chronic graft-versus-host disease tissue inflammation and fibrosis: a ROCKstar companion study
Belumosudil (KD025), an oral, selective, Rho-associated, coiled-coil–containing protein kinase 2 (ROCK2) inhibitor, is approved for third-line treatment of chronic graft-versus-host disease (cGVHD). Previous studies demonstrated that ROCK2 inhibition reduces blood interleukin-17 (IL-17) activity and promotes regulatory T-cell (Treg cell) recovery. However, these studies did not evaluate immune responses within cGVHD-affected tissues. This study assessed tissue-level immune dynamics in 20 patients with oral cGVHD from the phase 2 ROCKstar trial, before and after 6 months of belumosudil treatment, focusing on key effector sites (oral mucosa [OM], minor salivary glands [MSGs], and skin) and the peripheral blood. After belumosudil treatment, reduction in collagen was observed in OM in parallel with decreased IL-17+ cell frequency in both OM (n = 14 pairs) and MSG (n = 11 pairs). IL-17 was primarily produced by non–T cells in the oral tissues. Immune cell frequencies in the OM decreased after treatment, whereas CD4 Treg cells increased in both the MSG and blood. Per overall or mouth-specific clinical response criteria, responders to belumosudil exhibited a reduction in collagen type I and IL-17 in the OM. Additionally, salivary transforming growth factor β1 (TGF-β1), a critical driver of fibrosis, decreased significantly, with a strong correlation observed between TGF-β1 and IL-17 levels. These findings illustrate the tissue-level response to belumosudil therapy and suggest that there is a reduction in tissue fibrosis and inflammation, thereby highlighting the therapeutic impact of ROCK2 inhibition in mitigating cGVHD. The ROCKstar study was registered at www.ClinicalTrials.gov as #NCT03640481.
- 10 July 2025
- Published by American Society of Hematology in Blood Advances
- Vol. 9 (14) , 3479-3494
Open AccessBelumosudil reduces oral chronic graft-versus-host disease tissue inflammation and fibrosis: a ROCKstar companion study
Belumosudil (KD025), an oral, selective, Rho-associated, coiled-coil–containing protein kinase 2 (ROCK2) inhibitor, is approved for third-line treatment of chronic graft-versus-host disease (cGVHD). Previous studies demonstrated that ROCK2 inhibition reduces blood interleukin-17 (IL-17) activity and promotes regulatory T-cell (Treg cell) recovery. However, these studies did not evaluate immune responses within cGVHD-affected tissues. This study assessed tissue-level immune dynamics in 20 patients with oral cGVHD from the phase 2 ROCKstar trial, before and after 6 months of belumosudil treatment, focusing on key effector sites (oral mucosa [OM], minor salivary glands [MSGs], and skin) and the peripheral blood. After belumosudil treatment, reduction in collagen was observed in OM in parallel with decreased IL-17+ cell frequency in both OM (n = 14 pairs) and MSG (n = 11 pairs). IL-17 was primarily produced by non–T cells in the oral tissues. Immune cell frequencies in the OM decreased after treatment, whereas CD4 Treg cells increased in both the MSG and blood. Per overall or mouth-specific clinical response criteria, responders to belumosudil exhibited a reduction in collagen type I and IL-17 in the OM. Additionally, salivary transforming growth factor β1 (TGF-β1), a critical driver of fibrosis, decreased significantly, with a strong correlation observed between TGF-β1 and IL-17 levels. These findings illustrate the tissue-level response to belumosudil therapy and suggest that there is a reduction in tissue fibrosis and inflammation, thereby highlighting the therapeutic impact of ROCK2 inhibition in mitigating cGVHD. The ROCKstar study was registered at www.ClinicalTrials.gov as #NCT03640481.
- 8 March 2025
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 60 (5) , 725-728
Prevalence of clonal hematopoiesis of indeterminate potential in patients with severe chronic graft-versus-host disease
- 8 March 2025
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 60 (5) , 725-728
Prevalence of clonal hematopoiesis of indeterminate potential in patients with severe chronic graft-versus-host disease
- Open Access
- 4 October 2024
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 30 (9) , S597-S609
Improving Outcomes in Allogeneic Transplantation and Chronic Graft-versus-Host Disease Patients through Lifestyle Medicine: Current Landscape and Future Directions
- 4 October 2024
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 30 (9) , S597-S609
Open AccessImproving Outcomes in Allogeneic Transplantation and Chronic Graft-versus-Host Disease Patients through Lifestyle Medicine: Current Landscape and Future Directions
- Open Access
- 15 August 2024
- Published by American Society of Hematology in Blood Advances
- Vol. 8 (16) , 4294-4310
High-dose alemtuzumab and cyclosporine vs tacrolimus, methotrexate, and sirolimus for chronic graft-versus-host disease prevention
Chronic graft-versus-host disease (cGVHD) remains a significant problem for patients after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Although in vivo lymphodepletion for cGVHD prophylaxis has been explored in the myeloablative setting, its effects after reduced-intensity conditioning (RIC) are not well described. Patients (N = 83) with hematologic malignancies underwent targeted lymphodepletion chemotherapy followed by a RIC allo-HSCT using peripheral blood stem cells from unrelated donors. Patients were randomized to 2 GVHD prophylaxis arms: alemtuzumab and cyclosporine (AC; n = 44) or tacrolimus, methotrexate, and sirolimus (TMS; n = 39), with the primary end point of cumulative incidence of severe cGVHD. The incidence of severe cGVHD was lower with AC vs TMS prophylaxis at 1- and 5-years (0% vs 10.3% and 4.5% vs 28.5%; overall, P = .0002), as well as any grade (P = .003) and moderate-severe (P < .0001) cGVHD. AC was associated with higher rates of grade 3 to 4 infections (P = .02) and relapse (52% vs 21%; P = .003) with no difference in 5-year GVHD-free-, relapse-free-, or overall survival. AC severely depleted naïve T-cell reconstitution, resulting in reduced T-cell receptor repertoire diversity, smaller populations of CD4Treg and CD8Tscm, but a higher ratio of Treg to naïve T-cells at 6 months. In summary, an alemtuzumab-based regimen successfully reduced the rate and severity of cGVHD after RIC allo-HSCT and resulted in a distinct immunomodulatory profile, which may have reduced cGVHD incidence and severity. However, increased infections and relapse resulted in a lack of survival benefit after long-term follow-up. This trial was registered at www.ClinicalTrials.gov as #NCT00520130.
- 15 August 2024
- Published by American Society of Hematology in Blood Advances
- Vol. 8 (16) , 4294-4310
Open AccessHigh-dose alemtuzumab and cyclosporine vs tacrolimus, methotrexate, and sirolimus for chronic graft-versus-host disease prevention
Chronic graft-versus-host disease (cGVHD) remains a significant problem for patients after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Although in vivo lymphodepletion for cGVHD prophylaxis has been explored in the myeloablative setting, its effects after reduced-intensity conditioning (RIC) are not well described. Patients (N = 83) with hematologic malignancies underwent targeted lymphodepletion chemotherapy followed by a RIC allo-HSCT using peripheral blood stem cells from unrelated donors. Patients were randomized to 2 GVHD prophylaxis arms: alemtuzumab and cyclosporine (AC; n = 44) or tacrolimus, methotrexate, and sirolimus (TMS; n = 39), with the primary end point of cumulative incidence of severe cGVHD. The incidence of severe cGVHD was lower with AC vs TMS prophylaxis at 1- and 5-years (0% vs 10.3% and 4.5% vs 28.5%; overall, P = .0002), as well as any grade (P = .003) and moderate-severe (P < .0001) cGVHD. AC was associated with higher rates of grade 3 to 4 infections (P = .02) and relapse (52% vs 21%; P = .003) with no difference in 5-year GVHD-free-, relapse-free-, or overall survival. AC severely depleted naïve T-cell reconstitution, resulting in reduced T-cell receptor repertoire diversity, smaller populations of CD4Treg and CD8Tscm, but a higher ratio of Treg to naïve T-cells at 6 months. In summary, an alemtuzumab-based regimen successfully reduced the rate and severity of cGVHD after RIC allo-HSCT and resulted in a distinct immunomodulatory profile, which may have reduced cGVHD incidence and severity. However, increased infections and relapse resulted in a lack of survival benefit after long-term follow-up. This trial was registered at www.ClinicalTrials.gov as #NCT00520130.
- 14 September 2023
- Published by American Society of Hematology in Blood
- Vol. 142 (11) , 946-948
W“H-Y” antigen/HLA complexes in chronic GVHD
- 14 September 2023
- Published by American Society of Hematology in Blood
- Vol. 142 (11) , 946-948
W“H-Y” antigen/HLA complexes in chronic GVHD
- Open Access
- 29 August 2022
- Published by American Society of Hematology in Blood Advances
- Vol. 6 (17) , 4987-4988
A starting point for the phenotypic classification of pulmonary chronic graft-versus-host disease
Yifan Pang, Ananth V. Charya, Michael B. Keller, Arlene Sirajuddin, Yi-Ping Fu, Noa G. Holtzman, Steven Z Pavletic, Sean Agbor-Enoh; A starting point for the ph
- 29 August 2022
- Published by American Society of Hematology in Blood Advances
- Vol. 6 (17) , 4987-4988
Open AccessA starting point for the phenotypic classification of pulmonary chronic graft-versus-host disease
Yifan Pang, Ananth V. Charya, Michael B. Keller, Arlene Sirajuddin, Yi-Ping Fu, Noa G. Holtzman, Steven Z Pavletic, Sean Agbor-Enoh; A starting point for the ph
- Open Access
- 19 July 2022
- Published by American Society of Hematology in Blood Advances
- Vol. 6 (14) , 4196-4207
The ISHLT chronic lung allograft dysfunction consensus criteria are applicable to pulmonary chronic graft-versus-host disease
Pulmonary chronic graft-versus-host disease (PcGVHD) is a devastating complication of allogeneic hematopoietic stem cell transplant (HCT). The 2014 National Institutes of Health cGVHD consensus criteria (NIH criteria) only captures bronchiolitis obliterans syndrome (BOS). In this study, we adapted the 2019 International Society for Heart and Lung Transplantation (ISHLT) criteria of chronic lung allograft dysfunction (CLAD) to define novel phenotypes of PcGVHD and compared the performance of this criteria with the NIH criteria to identify patients with high-risk PcGVHD. We reviewed consecutive patients in a cGVHD natural history protocol (#NCT00092235) and adapted the 2019 CLAD criteria (the adapted criteria) to define PcGVHD as post-HCT forced expiratory volume at 1 second < 80% predicted value, with 4 phenotypes: obstructive, restrictive, mixed obstructive/restrictive, and undefined. An independent adjudication committee evaluated subjects for diagnosis and phenotyping. We identified 166 (47.4%) patients who met the adapted criteria, including obstruction (n = 12, 3.4%), restriction (n = 67, 19.1%), mixed obstruction/restriction (n = 47, 13.4%), and undefined (n = 40, 11.4%). In these patients, less than half (n = 78) met the NIH criteria for BOS (NIH+); the rest (n = 88) did not (NIH−). The NIH− subjects showed increased risk of death compared with those without PcGVHD (hazard ratio = 1.88, 95% confidence interval = 1.20-2.95; P = .006) that was similar to NIH+ subjects (P = .678). Our study demonstrated the potential of the adapted criteria in identifying patients with high-risk PcGVHD that have been missed by the NIH criteria. The adapted criteria could become a valuable tool to better phenotype and study lung disease in cGVHD.
- 19 July 2022
- Published by American Society of Hematology in Blood Advances
- Vol. 6 (14) , 4196-4207
Open AccessThe ISHLT chronic lung allograft dysfunction consensus criteria are applicable to pulmonary chronic graft-versus-host disease
Pulmonary chronic graft-versus-host disease (PcGVHD) is a devastating complication of allogeneic hematopoietic stem cell transplant (HCT). The 2014 National Institutes of Health cGVHD consensus criteria (NIH criteria) only captures bronchiolitis obliterans syndrome (BOS). In this study, we adapted the 2019 International Society for Heart and Lung Transplantation (ISHLT) criteria of chronic lung allograft dysfunction (CLAD) to define novel phenotypes of PcGVHD and compared the performance of this criteria with the NIH criteria to identify patients with high-risk PcGVHD. We reviewed consecutive patients in a cGVHD natural history protocol (#NCT00092235) and adapted the 2019 CLAD criteria (the adapted criteria) to define PcGVHD as post-HCT forced expiratory volume at 1 second < 80% predicted value, with 4 phenotypes: obstructive, restrictive, mixed obstructive/restrictive, and undefined. An independent adjudication committee evaluated subjects for diagnosis and phenotyping. We identified 166 (47.4%) patients who met the adapted criteria, including obstruction (n = 12, 3.4%), restriction (n = 67, 19.1%), mixed obstruction/restriction (n = 47, 13.4%), and undefined (n = 40, 11.4%). In these patients, less than half (n = 78) met the NIH criteria for BOS (NIH+); the rest (n = 88) did not (NIH−). The NIH− subjects showed increased risk of death compared with those without PcGVHD (hazard ratio = 1.88, 95% confidence interval = 1.20-2.95; P = .006) that was similar to NIH+ subjects (P = .678). Our study demonstrated the potential of the adapted criteria in identifying patients with high-risk PcGVHD that have been missed by the NIH criteria. The adapted criteria could become a valuable tool to better phenotype and study lung disease in cGVHD.